Article · Wikipedia archive · Last revised Jul 8, 2026

Nolomirole

Nolomirole (INNTooltip International Nonproprietary Name; developmental code name CHF-1035), also known as 5,6-diisobutyryloxy-N-methyl-2-aminotetralin, is a dual dopamine D2 and α2-adrenergic receptor agonist which was under development for the treatment of heart failure but was never marketed. It is taken orally.

Last revised
Jul 8, 2026
Read time
≈ 2 min
Length
370 w
Citations
20
Source
Wikipedia ↗
Nolomirole
Clinical data
Other namesCHF-1035; CHF1035; 5,6-Diisobutyryloxy-N-methyl-2-aminotetralin; 5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene; 5,6,7,8-Tetrahydro-6-(methylamino)-1,2-naphthylene diisobutyrate; N-Methyl-2-aminotetralin
Routes of
administration		Oral12
Drug classDopamine D2 receptor agonist; α2-Adrenergic receptor agonist
ATC code
  • None
Identifiers
  • [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H27NO4
Molar mass333.428 g·mol−1
3D model (JSmol)
  • CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C
  • InChI=1S/C19H27NO4/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4/h6,9,11-12,14,20H,7-8,10H2,1-5H3
  • Key:OMMYLOLVPCCZQZ-UHFFFAOYSA-N

Nolomirole (INNTooltip International Nonproprietary Name; developmental code name CHF-1035), also known as 5,6-diisobutyryloxy-N-methyl-2-aminotetralin, is a dual dopamine D2 and α2-adrenergic receptor agonist which was under development for the treatment of heart failure but was never marketed.1234 It is taken orally.12

Pharmacology

The drug acts as an agonist of the dopamine D2 receptor, with an affinity (Ki) of 120 nM for the (–)- enantiomer and 2,400 nM for the (+)- enantiomer, and as an agonist of the α2-adrenergic receptor, with an affinity (Ki) of 130 nM for the (–)- enantiomer and 1,600 nM for the (+)- enantiomer.12 It is a prodrug of CHF-1024 (5,6-dihydroxy-N-methyl-2-aminotetralin), to which it is rapidly hydrolyzed by circulating esterase enzymes.1 The elimination half-life of nolomirole is said to be 3 hours and its log P is 1.97.3

Chemistry

Nolomirole and its active form CHF-1024 are cyclized phenethylamines and 2-aminotetralin analogues of the catecholamine neurotransmitter dopamine and its N-methyl derivative epinine (deoxyepinephrine, N-methyldopamine).12

History

Nolomirole was first described in the scientific literature by 1992.15 It was being developed by the pharmaceutical company Chiesi Farmaceutici in the 1990s and 2000s.14 Nolomirole reached phase 3 clinical trials prior to the discontinuation of its development.14

See also

See also

References

References

  1. Leeson PA, Bayes M, Castaner J, Mealy NE (2001). "Nolomirole Hydrochloride". Drugs of the Future. 26 (11): 1046. doi:10.1358/dof.2001.026.11.642071. Retrieved 19 June 2025.
  2. Tang WH, Francis GS (November 2003). "Novel pharmacological treatments for heart failure". Expert Opinion on Investigational Drugs. 12 (11): 1791–1801. doi:10.1517/13543784.12.11.1791. PMID 14585055.
  3. Dörwald FZ (4 February 2013). Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. ISBN 978-3-527-64565-7. Retrieved 19 June 2025.
  4. "Nolomirole hydrochloride". AdisInsight. 9 January 2002. Retrieved 19 June 2025.
  5. Fronza G, Bovis G, Ventura P, Redenti E (1992). "Application of γ-cyclodextrin to enantiomeric purity determination of a new 2-amino-tetralin derivative by 1 H-NMR spectroscopy". Chirality. 4 (6): 404–405. doi:10.1002/chir.530040613. ISSN 0899-0042. Retrieved 19 June 2025.